JP2014530882A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530882A5
JP2014530882A5 JP2014537380A JP2014537380A JP2014530882A5 JP 2014530882 A5 JP2014530882 A5 JP 2014530882A5 JP 2014537380 A JP2014537380 A JP 2014537380A JP 2014537380 A JP2014537380 A JP 2014537380A JP 2014530882 A5 JP2014530882 A5 JP 2014530882A5
Authority
JP
Japan
Prior art keywords
optionally substituted
hydrogen
group
structural formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014537380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530882A (ja
JP6196224B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/061737 external-priority patent/WO2013063149A1/en
Publication of JP2014530882A publication Critical patent/JP2014530882A/ja
Publication of JP2014530882A5 publication Critical patent/JP2014530882A5/ja
Application granted granted Critical
Publication of JP6196224B2 publication Critical patent/JP6196224B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014537380A 2011-10-24 2012-10-24 シアル酸類似体 Active JP6196224B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161550610P 2011-10-24 2011-10-24
US61/550,610 2011-10-24
PCT/US2012/061737 WO2013063149A1 (en) 2011-10-24 2012-10-24 Sialic acid analogs

Publications (3)

Publication Number Publication Date
JP2014530882A JP2014530882A (ja) 2014-11-20
JP2014530882A5 true JP2014530882A5 (enExample) 2015-09-10
JP6196224B2 JP6196224B2 (ja) 2017-09-13

Family

ID=48168447

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014537380A Active JP6196224B2 (ja) 2011-10-24 2012-10-24 シアル酸類似体

Country Status (13)

Country Link
US (5) US8840926B2 (enExample)
EP (1) EP2771348B1 (enExample)
JP (1) JP6196224B2 (enExample)
KR (1) KR102049214B1 (enExample)
CN (1) CN103974965B (enExample)
AU (1) AU2012328874B2 (enExample)
BR (1) BR112014009760B1 (enExample)
CA (1) CA2849114C (enExample)
ES (1) ES2807890T3 (enExample)
HK (1) HK1201067A1 (enExample)
IL (1) IL231714B (enExample)
MX (1) MX347541B (enExample)
WO (1) WO2013063149A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241896B2 (en) 2008-12-19 2016-01-26 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
BR112013000776A2 (pt) 2010-07-13 2016-05-24 Ultragenyx Pharmaceutical Inc método e formulação para tratamento de deficiência de ácido siálico
WO2013063149A1 (en) 2011-10-24 2013-05-02 Ultragenyx Pharmaceutical, Inc. Sialic acid analogs
CN104271125A (zh) * 2012-01-18 2015-01-07 奥特吉尼克斯制药公司 用于治疗唾液酸缺乏的方法和制剂
WO2017048817A1 (en) 2015-09-14 2017-03-23 Ultragenyx Pharmaceutical Inc. Crystal forms of sialic acid or salt or solvate thereof
CN121079430A (zh) * 2023-02-17 2025-12-05 奥特吉尼克斯制药公司 唾液酸衍生物的结晶形式及其使用方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6168418A (ja) 1984-09-11 1986-04-08 Kanto Ishi Pharma Co Ltd 去痰薬
JPS63139193A (ja) * 1986-11-28 1988-06-10 Mect Corp シアル酸誘導体1,7−ラクトン
US6156544A (en) 1993-06-09 2000-12-05 Glaxo Group Limited Process for the preparation of N-acetylneuraminic acid
CA2215978A1 (en) 1995-04-04 1996-10-10 Wound Healing Of Oklahoma Cancer treatment by photodynamic therapy, in combination with an immunoadjuvant
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
WO1999052931A1 (fr) 1998-04-10 1999-10-21 Mitsubishi Chemical Corporation Dispersion solide contenant un derive d'acide sialique
KR20030006721A (ko) 2001-07-14 2003-01-23 삼성전자 주식회사 리소그라피 시스템 및 이를 이용한 레티클 표면의 파티클제거방법
BR0311978A (pt) 2002-06-21 2005-03-22 Novo Nordisk Healthcare Ag Preparação, método para preparar a mesma, formulação farmacêutica, métodos para tratar de uma sìndrome responsiva ao fator vii, para prevenir hemorragias indesejáveis, para prevenir coagulação sanguìnea indesejável e para prevenir as reações mediadas pelo fator tecidual, e, uso de uma preparação
US7238677B2 (en) 2003-03-28 2007-07-03 Kimberly-Clark Worldwide, Inc. Prevention of urogenital infections
AU2004296404A1 (en) * 2003-12-09 2005-06-23 Spherics, Inc. Bioadhesive polymers with catechol functionality
KR101202607B1 (ko) 2005-03-03 2012-11-20 마나테크 인코포레이티드 영양 보조제의 조절된 방출을 위한 방법 및 조성물
WO2007103286A2 (en) * 2006-03-02 2007-09-13 Spherics, Inc. Rate-controlled bioadhesive oral dosage formulations
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
WO2008150477A2 (en) 2007-05-31 2008-12-11 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health N-acetyl mannosamine as a therapeutic agent
CA2698108A1 (en) 2007-08-27 2009-03-12 Massachusetts Institute Of Technology Bi-functional polymer-attached inhibitors of influenza virus
WO2009137827A2 (en) 2008-05-09 2009-11-12 Tiara Pharmaceuticals, Inc. Controlled release of n-acetylcysteine (nac) for reduction of systemic and/or vascular inflammation
KR101116864B1 (ko) 2008-08-01 2012-02-29 주식회사 베네비오 고지혈증, 지방간 또는 비만의 예방 또는 치료용 조성물
US9241896B2 (en) 2008-12-19 2016-01-26 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
US20100160363A1 (en) 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
US20100159001A1 (en) 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
JP5626734B2 (ja) * 2009-05-15 2014-11-19 公益財団法人ヒューマンサイエンス振興財団 Gneタンパク質の機能低下に起因する疾患の治療用医薬剤、食品組成物
BR112013000776A2 (pt) 2010-07-13 2016-05-24 Ultragenyx Pharmaceutical Inc método e formulação para tratamento de deficiência de ácido siálico
WO2013063149A1 (en) 2011-10-24 2013-05-02 Ultragenyx Pharmaceutical, Inc. Sialic acid analogs
CN104271125A (zh) 2012-01-18 2015-01-07 奥特吉尼克斯制药公司 用于治疗唾液酸缺乏的方法和制剂
EP3252065B1 (en) 2015-01-28 2020-01-08 Kyowa Hakko Bio Co., Ltd. Crystal of ammonium n-acetylneuraminate anhydrate, and process for producing same
WO2017048817A1 (en) 2015-09-14 2017-03-23 Ultragenyx Pharmaceutical Inc. Crystal forms of sialic acid or salt or solvate thereof

Similar Documents

Publication Publication Date Title
KR102666477B1 (ko) 글루타민 유사체의 프로드럭
ES2970715T3 (es) Composiciones y métodos para inhibir la actividad de la arginasa
CN113423685A (zh) 整合应激通路的前药调节剂
ES2694328T3 (es) Composición acuosa líquida
WO2019110773A1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
AR064304A1 (es) Formulaciones de ansamicina y sus metodos de uso
RU2012108874A (ru) Композиции, содержащие расщепляемые ферментами опиоидные пролекарства с модифицированным кетоном и их дополнительные ингибиторы
EP3740229A1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
JP7650228B2 (ja) 官能化シクロオクテンを調製するためのプロセス
WO2019110837A1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
JP2019503356A5 (enExample)
JP2018527360A (ja) 修飾された細胞毒とその治療的使用
JP7376694B2 (ja) 再生可能資源に由来するポリマーおよび組成物
WO2016136641A1 (ja) 生理活性物質結合ブロック共重合体
ES2884123T3 (es) Formulaciones de inhibidores de xantina oxidasa
EP3720471A1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
JP2016536372A5 (enExample)
EP4076420A1 (en) Compounds for the treatment of bacterial infections and potentiation of antibiotics
EP3378495B1 (en) Composition comprising novel glutamic acid derivative and block copolymer, and use thereof
CN113365617B (zh) 用于医学疾病治疗的一氧化碳前药
JP7506660B2 (ja) デンドリマー製剤
ITMI20120121A1 (it) Nuovi composti antitumorali
JP6454030B2 (ja) ペプチドホウ酸化合物を含有する安定化薬学製剤
US10945997B2 (en) Polymer derivative of macrolide immunosuppressant
WO2015192052A1 (en) Egfr targeting compounds and methods of use thereof